Artemisinin and Babesia: why the evidence is interesting—and genuinely mixed.

What the experiments actually found

2021: activity against Babesia duncani in vitro

A Johns Hopkins-affiliated study published in Frontiers in Cellular and Infection Microbiology tested botanical extracts and purified compounds against B. duncani growing in erythrocytes. Artemisinin inhibited growth with an IC₅₀ of about 14 μM. Artesunate and artemether were more active in that system, with reported IC₅₀ values of approximately 7.4 μM and 7.8 μM.

The regrowth experiments are especially important for interpretation. Artemether at a high multiple of its IC₅₀ prevented regrowth under the reported subculture conditions, whereas Artemisia annua extract and artesunate-treated cultures could regrow in several conditions. In other words, the paper demonstrated measurable activity but did not show that every artemisinin preparation sterilized the culture.

2021: a negative B. microti mouse experiment

A separate study tested artemisinin, artesunate and dried A. annua leaf material in mice infected with B. microti. Under that protocol, none significantly reduced or eliminated parasitemia compared with control animals. The authors concluded that those preparations were ineffective in their B. microti model.

This negative result matters because it shows why results from B. duncani cannot simply be copied onto B. microti. Babesia species differ in phylogeny, metabolism, drug susceptibility and red-cell biology.

2024: artesunate showed benefit in a different B. microti mouse study

A later murine study reported dose-dependent reductions in B. microti parasite burden after artesunate treatment and improvements in hematologic and tissue-injury markers. That creates a genuine conflict in the animal literature rather than a simple yes/no answer. Differences in strain, dose, route of administration, timing, animal model and endpoints can all change experimental outcomes.

“Natural” does not mean pharmacologically inactive.

Artemisinin compounds are biologically active drugs. Product quality, concentration, metabolism, drug interactions and adverse effects matter. Published malaria protocols use standardized pharmaceutical derivatives in carefully defined regimens; that is very different from assuming that any Artemisia annua supplement has equivalent pharmacology.

Because babesiosis can become severe and because established prescription treatments exist, experimental botanical use should not delay diagnosis or indicated medical therapy.